Please ensure Javascript is enabled for purposes of website accessibility

Key Takeaways From J&J's Big Quarter

By Dave Williamson - Apr 16, 2013 at 5:38PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Johnson & Johnson makes a strong showing this quarter. What do you need to know from the report?

In this video, David Williamson reviews Johnson & Johnson's latest earnings report. The over-the-counter and nutritional business both grew, as did the pharma division, with a blood thinner holding its own and a new diabetes drug that looks promising. Medical devices saw a 10% uptick, but that was considered a disappointment in light of recent acquisitions.

David says he's neutral on the stock, but he also notes its 2.9% dividend and thinks it could prove to be a safe long-term investment. Check out the video for more details.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$179.96 (-0.80%) $-1.45
Pfizer Inc. Stock Quote
Pfizer Inc.
$53.51 (0.18%) $0.10
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$77.25 (0.16%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.